Alberto Purwada was a Senior Analyst at CBPartners.
Connect with Alberto Purwada
PART I of CBPartners' CNS series: as the scientific and regulatory barriers in Parkinson’s disease are beginning to be addressed, biotechnology firms are developing innovative therapies based on academic studies showing potential therapeutic targets and pathways, which have been generated with increasing quantity over the past few years using genetic and pre-clinical studies.
PART I of CBPartners' CNS series: the concept of external investment may represent a positive trend in the neuroscience space where different size firms are focused on their comparative strengths.
PART II of CBPartners' CNS series:
CBPartners uncovers the most impactful clinical considerations for commercial PDx success in this handy infographic.
VC investment in digital healthcare has been growing rapidly (+42% vs. 2017) as the potential of new technology to solve complex issues, ranging from providing healthcare services to managing chronic conditions, evolves. CBPartners takes a look at investment trends in digital health.